used multispectral imaging to identify features in pre‐treatment melanoma specimens, such as CD163+ PD‐L1− myeloid cells and CD8+ FoxP3+ PD‐1low/mid T cells, that predict response to anti‐PD‐1 therapy and stratify long‐term survival after treatment.[245] Chu et al. The gene discussed is CD8A; the disease is melanoma.